Background: Daptomycin pharmacokinetics has not been extensively studied in patients undergoing continuous renal replacement therapy (CRRT). Methods: The aim of the study was to collect pharmacokinetics and clinical data of patients undergoing CRRT and receiving daptomycin therapy. Daptomycin was measured using an isocratic high-performance liquid chromatography technique. Results: Three patients with bloodstream infection underwent CVVHD and three CVVHDF. CVVHDF patients had significantly lower mean AUC0224 and Cmax values. A significant decrease in plasma levels was observed in a CVVHDF patient using ‘high cut-off’ hemofilters. Conclusion: Increasing doses of daptomycin should be considered in critical patients, especially those undergoing CVVHDF.

Daptomycin serum levels in critical patients undergoing continuous renal replacement / M. Falcone; A. Russo; M.I. Cassetta; A. Lappa; L. Tritapepe; S. Fallani; V. Vullo; M. Venditti; A. Novelli. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1973-9478. - ELETTRONICO. - 24:(2012), pp. 253-256. [10.1179/1973947812Y.0000000033]

Daptomycin serum levels in critical patients undergoing continuous renal replacement

CASSETTA, MARIA IRIS;FALLANI, STEFANIA;NOVELLI, ANDREA
2012

Abstract

Background: Daptomycin pharmacokinetics has not been extensively studied in patients undergoing continuous renal replacement therapy (CRRT). Methods: The aim of the study was to collect pharmacokinetics and clinical data of patients undergoing CRRT and receiving daptomycin therapy. Daptomycin was measured using an isocratic high-performance liquid chromatography technique. Results: Three patients with bloodstream infection underwent CVVHD and three CVVHDF. CVVHDF patients had significantly lower mean AUC0224 and Cmax values. A significant decrease in plasma levels was observed in a CVVHDF patient using ‘high cut-off’ hemofilters. Conclusion: Increasing doses of daptomycin should be considered in critical patients, especially those undergoing CVVHDF.
2012
24
253
256
M. Falcone; A. Russo; M.I. Cassetta; A. Lappa; L. Tritapepe; S. Fallani; V. Vullo; M. Venditti; A. Novelli
File in questo prodotto:
File Dimensione Formato  
Falcone M Daptomycin 2012.pdf

Accesso chiuso

Tipologia: Altro
Licenza: Tutti i diritti riservati
Dimensione 132.08 kB
Formato Adobe PDF
132.08 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/792346
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 17
social impact